Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes

• Published in: Metabolism, clinical and experimental clinical and experimental, 1999-07, Vol.48 (7), p.897-903
• Main Authors: Tessier, Daniel, Maheux, Pierre, Khalil, Abdelouahed, Fülöp, Tamas
• Format: Article
• Language: English
• Subjects: Aged; Biological and medical sciences; Biomarkers; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - physiopathology; Female; Gliclazide - adverse effects; Gliclazide - therapeutic use; Hormones. Endocrine system; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Lipid Peroxides - metabolism; Lipoproteins, HDL - blood; Lipoproteins, LDL - blood; Male; Medical sciences; Metformin - adverse effects; Metformin - therapeutic use; Middle Aged; Pharmacology. Drug treatments; Treatment Outcome; Vitamin E - blood
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/S0026-0495(99)90226-3

The sulfonylurea gliclazide and the biguanide metformin have different mechanisms to reduce glycemia. We performed a randomized study to compare these two agents with respect to glycemic control and effects on lipid peroxidation markers in 36 adult patients with type 2 diabetes. Both agents significantly decreased glycosylated hemoglobin ([HbA 1c] P < .05), fructosamine ( P < .05), and the glucose-excursion curve during the oral glucose tolerance test ([OGTT] P < .01). With regard to the insulin curve during this test, no significant change was observed with metformin and a significant increase was measured with gliclazide ( P < .05). Considering the small number of events, no significant difference was detected in the number of hypoglycemic episodes between the two agents. More upper-gastrointestinal (GI) symptoms were observed with metformin compared with gliclazide ( P < .05). Even with no change in the standard lipid profile, both agents increased serum vitamin E ( P < .01) for gliclazide and P < .05 for metformin) and decreased the level of lipid peroxidation markers in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles ( P < .05). Despite different mechanisms of action, gliclazide and metformin demonstrated comparable levels of efficacy and complementary effects on lipid peroxidation markers.